Multidrug-resistant myeloma laboratory clinical effects verapamil chemosensitizer Verapamil chemosensitizer multidrug resistance multiple myeloma vitro clinical trials Bone myeloma patients relapse several resistance parameters expression p-glycoprotein Adriamycin vincristine sensitivity ability added verapamil resistance cytotoxic agents verapamil capable myeloma cells resistance vitro sensitivity cells drug sensitive Myeloma cells doxorubicin resistant vitro cells clinical trials patients myeloma refractory vincristine-Adriamycin-dexamethasone VAD VAD high-dose intravenous verapamil Ve patients VAD/Ve partial remission median relapse-free survival VAD/Ve responders months overall survival start VAD/Ve nonresponders subset patients myeloma cells positive whereas none patients myeloma cells remission VAD/Ve myeloma cells VAD/Ve clinical responders vitro chemosensitization verapamil whereas vitro verapamil chemosensitization clinical nonresponders observations clinical reversal multidrug resistance patients VAD-refractory myeloma use verapamil addition value drug development vitro tests expression chemosensitizers cytotoxic drugs patients bone marrow myeloma cells patients chemosensitizer-containing regimens chemosensitizer capable multidrug resistance role treatment hematologic malignancies B-cell neoplasms multiple myeloma non-Hodgkin lymphomas 